Traders should monitor future Form 4 filings for any actual insider buying or selling activity by Milligan, which could signal sentiment. The Power of Attorney itself is administrative and not indicative of imminent transactions.
Price Chart
Executive Summary
John Fairbanks Milligan, a director or officer of Kailera Therapeutics, filed a Form 3 to report initial beneficial ownership of stock options and established a Power of Attorney authorizing others to file SEC reports on his behalf. This is a routine compliance filing related to insider ownership disclosure.
Key Facts
- John Fairbanks Milligan filed a Form 3, indicating initial reporting of beneficial ownership of securities in Kailera Therapeutics, Inc. (KLRA).
- The filing discloses two stock options: one for 285,307 shares at $5.25 strike price expiring 2034, and another for 313,817 shares at $7.24 strike price expiring 2035.
- Vesting terms: 25% of the first option vested on September 19, 2025, with the remainder vesting in 36 equal monthly installments; the second option vests 25% on November 5, 2026, then monthly over 36 months, subject to continued service.
- Milligan granted a Power of Attorney to Scott Akamine, John Mei, and Corey Manchester to execute and file Section 16 and Form 144 documents on his behalf.
Financial Impact
No immediate financial impact; this is a disclosure of existing equity grants and administrative delegation.
Risk Factors
- Potential for future insider selling under Rule 144, though no immediate transactions are reported.
- Delayed or unexpected filings if the appointed attorneys fail to act promptly.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001193125-26-159636 |
| Document: 0001193125-26-159636-index-headers.html | 0001193125-26-159636 |
| Document: 0001193125-26-159636-index.html | 0001193125-26-159636 |
| Document: 0001193125-26-159636.txt | 0001193125-26-159636 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 22d ago | 3 | $14.91 $12.92 | ▼ −13.35% | ▼ −12.85% | $10.39 (−30.32%) |
Aug 12, 2026 7w ago | 8-K | $17.97 $17.47 | ▼ −2.78% | ▼ −0.82% | $10.39 (−42.18%) |
Jul 31, 2026 9w ago | Court Ruling | $16.94 $18.66 | ▲ +10.15% | ▲ +6.64% | $10.39 (−38.67%) |
Jul 24, 2026 10w ago | Court Ruling | $17.69 $17.05 | ▼ −3.62% | ▼ −3.99% | $10.39 (−41.27%) |
Jun 5, 2026 16w ago | Press Release | $19.70 $19.67 | ▼ −0.15% | ▼ −2.26% | $10.39 (−47.26%) |
May 26, 2026 18w ago | 8-K | $21.91 $22.38 | ▲ +2.15% | ▲ +1.68% | $10.39 (−52.58%) |
May 26, 2026 18w ago | Press Release | $21.91 $22.59 | ▲ +3.10% | ▲ +1.90% | $10.39 (−52.58%) |
May 13, 2026 20w ago | Press Release | $21.11 $19.62 | ▼ −7.06% | ▼ −5.90% | $10.39 (−50.78%) |
Apr 20, 2026 23w ago | 8-K | $25.22 $23.82 | ▼ −5.55% | ▼ −6.63% | $10.39 (−58.80%) |
Apr 20, 2026 23w ago | Insider Cluster | $24.61 $23.51 | ▼ −4.47% | ▼ −5.38% | $10.39 (−57.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access